Skip to content
Homepage
Author:
Verrica Pharmaceuticals Inc.
Posted Date:
July 30, 2026
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Verrica Pharmaceuticals Inc.
July 30, 2026
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica Pharmaceuticals Inc.
July 22, 2026
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals Inc.
June 22, 2026
